GlassScriptPhysician profile
James C Fleming
NPI 1912401761
$6,238.41
in general payments reported to CMS, 2019-2025
10 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what 82% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.97 · 2023: $3,307 · 2024: $913 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,055 · Food and Beverage: $2,162 · Education: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,055.16 |
| Food and Beverage | $2,162.47 |
| Education | $1,005.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,833.10 | 2023-2024 | Senza |
| Boston Scientific Corporation | $2,334.66 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Virtus Pharmaceuticals LLC | $282.99 | 2023-2024 | Levorphanol Tartrate |
| Globus Medical, INC. | $234.82 | 2025 | Senza |
| Medtronic, INC. | $169.51 | 2024 | Intellis Adaptivestim |
| Spr Therapeutics, INC | $121.40 | 2023 | Sprint Pns System |
| Saluda Medical Americas, INC. | $110.50 | 2025 | Evoke |
| Si-Bone, INC. | $82.33 | 2024 | |
| Stryker Corporation | $53.01 | 2022-2025 | Spinejack, Optablate |
| Ultragenyx Pharmaceutical INC. | $16.09 | 2024 | Dojolvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.